Meridia, or Sibutramine Hydrochloride Monohydrate, was a medication once used to treat obesity by suppressing appetite and aiding weight management. Administered in doses up to 15 mg, Meridia's active metabolites had longer half-lives than the drug itself. However, due to associated risks like increased blood pressure and potential side effects ranging from dry mouth to depression, it was withdrawn from use despite its effectiveness in clinical trials.

For those seeking alternatives, several options exist. Orlistat, Phentermine, Liraglutide (Saxenda/Victoza), Mounjaro, and Phendimetrazine are viable alternatives with varying mechanisms of action. Orlistat inhibits fat absorption, Phentermine suppresses appetite via the central nervous system, Liraglutide is a subcutaneous injection that aids weight loss, Mounjaro is administered via injection for weight management, and Phendimetrazine reduces appetite through central nervous system effects.

Each alternative requires a prescription and careful monitoring due to potential side effects and varying effectiveness based on individual health conditions. Consulting with healthcare professionals is essential to determine the most suitable treatment option for obesity management.

Overall, while Meridia provided effective weight loss benefits, its withdrawal necessitates exploring safer and more appropriate alternatives under medical supervision.